Role of COX-2, VEGF and cyclin D1 in mammary infiltrating duct carcinoma

Oncology Reports

Volumn 10, Issue 5, 2003, Pages 1241-1249

  Lim, Sung Chul ^a  

^a Chosun University College of Medicine   (South Korea)

Author keywords

Breast; Carcinoma; COX 2; Cyclin D1; Prognosis; VEGF

Indexed keywords

CYCLIN D1; CYCLOOXYGENASE 2; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PTGS2 PROTEIN, HUMAN; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; BREAST TUMOR; CELL NUCLEUS; CONFOCAL MICROSCOPY; CYTOPLASM; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PAGET NIPPLE DISEASE; PHYSIOLOGY; PROGNOSIS; TIME;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL NUCLEUS; CYCLIN D1; CYCLOOXYGENASE 2; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; LYMPHATIC METASTASIS; MEMBRANE PROTEINS; MICROSCOPY, CONFOCAL; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 1842841557     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.5.1241     Document Type: Article

References (46)

1. Page DL: Prognosis and breast cancer: recognition of lethal and favorable prognostic types. Am J Surg Pathol 15: 334-349, 1991.
2. Fisher ER: The impact of pathology on the biologic, diagnostic, prognostic and therapeutic considerations in breast cancer. Surg Clin North Am 64: 1073-1093, 1984.
3. Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T and McGuire WL: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320: 627-633, 1989. (Pubitemid 19072467)
4. Henderson BE, Ross RK, Pike MC and Casagrande JT: Endogenous hormones as a major factor in human cancer. Cancer Res 42: 3232-3239, 1982. (Pubitemid 12041084)
5. Pari FF, Schmidt BP, Dupont WD and Wagner RK: Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis and histopathologic grading. Cancer 54: 2237-2242, 1984. (Pubitemid 15210812)
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987. (Pubitemid 17231334)
7. Cattoretti G, Rilke F, Andreola S, D'Amato L and Delia D: p53 expression in breast cancer. Int J Cancer 41: 178-183, 1988. (Pubitemid 18061140)
8. Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I and Schmitt FC: Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 55: 429-434, 2002. (Pubitemid 34620779)
9. Ristimaki A, Silvula A, Lundin J, et al: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62: 632-635, 2002. (Pubitemid 34126931)
10. MacConmara M, O'Hanlon DM, Kiely MJ, Connolly Y, Jeffers M and Keane FB: An evaluation of the prognostic significance of vascular endothelial growth factor in node positive primary breast carcinoma. Int J Oncol 20: 717-721, 2002.
11. De Paola F, Granato AM, Scarpi E, et al: Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer. Int J Cancer 98: 228-233, 2002. (Pubitemid 34150807)
12. Williams CS, Mann M and DuBois RN: The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18: 7908-7916, 1999. (Pubitemid 30066236)
13. Martin-Sanz P, Callejas NA, Casado M, Diaz-Guerra MJ and Bosca L: Expression of cyclooxygenase-2 in foetal rat hepatocytes stimulated with lipopolysaccharide and pro-inflammatory cytokines. Br J Pharmacol 125: 1313-1319, 1998. (Pubitemid 28542542)
14. Callejas NA, Casado M, Diaz-Guerra MJM, Bosca L and Martin-Sanz P: Expression of cyclooxygenase-2 promotes the release of matrix metalloproteinase-2 and -9 in fetal rat hepatocytes. Hepatology 33: 860-867, 2001. (Pubitemid 32246635)
15. Sheng H, Shao J, Morrow JD, Beauchamp RD and DuBois RN: Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58: 362-366, 1998. (Pubitemid 28047080)
16. Sawaoka H, Kawano S, Tsuji S, et al: Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 274: G1061-G1067, 1998.
17. Battu S, Rigaud M and Beneytout JL: Resistance to apoptosis and cyclo-oxygenase-2 expression in a human adenocarcinoma cell line HT29CL.19A. Anticancer Res 18: 3579-3583, 1998. (Pubitemid 28546493)
18. Erikson BA, Longo WE, Panesar N, Mazuski JE and Kaminski DL: The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J Surg Res 81: 101-107, 1999. (Pubitemid 29393786)
19. Sheng GG, Shao J, Sheng H, et al: A selective cyclooxygenase-2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology 113: 1883-1891, 1997. (Pubitemid 27512146)
20. Kinoshita T, Takahashi Y, Sakashita T, Inoue H, Tanabe T and Yoshimoto T: Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenase-1 and -2 in human colon carcinoma cells. Biochem Biophys Acta 1438: 120-130, 1999. (Pubitemid 29238523)
21. Ben-Av P, Crofford LJ, Wilder RL and Hla T: Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett 372: 83-87, 1995.
22. Goodwin JS and Ceuppens J: Regulation of the immune response by prostaglandins. J Clin Immunol 3: 295-314, 1983.
23. Masferrer JL, Leahy KM, Koki AT, et al: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306-1311,2000. (Pubitemid 30151999)
24. Senger DR, van De Water L, Brown LF, et al: Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12: 303-324, 1993. (Pubitemid 23293287)
25. Cordon-Cardo C: Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 147: 545-560, 1995.
26. Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991.
27. Fisher ER, Sass R and Fisher B: Pathologic findings from the National Surgical Adjuvant Project for Breast Cancers (protocol No. 4). X. Discriminants for tenths year treatment failure. Cancer 53: 712-723, 1984. (Pubitemid 14190897)
28. AJCC Cancer Staging Manual. Lippincott-Raven, Philadelphia, pp171-180, 1997.
29. Folkman J: How is blood vessel growth regulated in normal and neoplastic tissue. Cancer Res 46: 467-473, 1986.
30. Keck PJ, Hauser SD, Krivi G, et al: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246: 1309-1312, 1989. (Pubitemid 20066717)
31. Folkman J and Shing Y: Angiogenesis. J Biol Chem 267: 10931-10934, 1992.
32. Dvorak HF, Orenstein NS, Carvalho AC, et al: Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor secreted by products. J Immunol 122: 166-174, 1979. (Pubitemid 9078536)
33. Houck KA, Ferrara N, Winer J, Cachianes G, Li B and Leung DW: The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 3: 1806-1814, 1991.
34. Horak E, Leek R, Klenk N, Lejeune S, Smith K and Stuart N: Angiogenesis assessed by platelet endothelial cell adhesion molecule antibodies, as an indicator of node metastasis and survival in breast cancer. Lancet 340: 1120-1124, 1992.
35. Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A and Trapasso F: Upregulation of vascular endothelial growth factor and down regulation of placenta growth factor associated with malignancy in human thyroid tumors and cell lines. Oncogene 11: 1569-1579, 1995.
36. Frank S, Hubner G, Breier G, Longaker MT, Greenhalgh DG and Werner S: Regulation of VEGF expression in cultured keratinocytes. Implication for normal and impaired wound healing. J Biol Chem 270: 12607-12613, 1995.
37. Kieser A, Weich HA, Brandner G, Marme D and Kolch W: Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9: 963-969 1994. (Pubitemid 24065938)
38. Dvorak HF: Tumors: wounds that do not heal. Similarity between tumor stroma generation and wound healing. N Engl J Med 315: 1650-1658, 1986.
39. Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A and Weinberg RA: Physical interaction of the retinoblastoma protein with human D cyclins. Cell 73: 499-511, 1993. (Pubitemid 23143349)
40. Kim SH, Lewis JJ, Brennan MF, Woodruff JM, Dudas M and Cordon-Cardo C: Overexpression of cyclin D1 is associated with poor prognosis in extremity soft-tissue sarcomas. Clin Cancer Res 4: 2377-2382, 1998. (Pubitemid 28477902)
41. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D and Peters G: Amplification and overexpression of cyclin D1 in breast cancer detected by imrnunohistochemical staining. Cancer Res 54: 1812-1817, 1994. (Pubitemid 24116192)
42. Van Diest PJ, Michalides RJ, Jannink L, van der Valk P, Peterse HL, Meijer CJ and Baak JP: Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol 150: 705-711, 1997. (Pubitemid 27073797)
43. Michalides R, Hageman P, van Tinteren H, Houben L, Wientjens E and Peterse J: A clinicopathologic study on overexpression of cyclin D1 and p53 in a series of 248 patients with operable breast cancer. Br J Cancer 73: 728-734, 1996. (Pubitemid 26105298)
44. Akervall JA, Michalides RJ, Mineta H, et al: Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer 79: 380-390, 1997.
45. Zhang SY, Caamano J, Cooper F, Guo X and Klein-Szanto AJ: Immunohistochemistry of cyclin D1 in human breast cancer Am J Clin Pathol 102: 695-698, 1994. (Pubitemid 24337568)
46. Musgrove EA, Hamilton JA, Lee CS, Sweeney KJ, Watts CK and Sutherland RL: Growth factor steroid and steroid antagonist regulation of cyclin gene expression associated with changes in T47D human breast cancer cell cycle progression. Mol Cell Biol 13: 3577-3587, 1993. (Pubitemid 23157295)